Knight Therapeutics Inc. Stock price

Equities

GUD

CA4990531069

Pharmaceuticals

Market Closed - Toronto S.E. 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
5.3 CAD -2.57% Intraday chart for Knight Therapeutics Inc. +1.34% +2.12%
Sales 2024 * 345M 255M Sales 2025 * 359M 265M Capitalization 536M 395M
Net income 2024 * 3M 2.21M Net income 2025 * 2M 1.48M EV / Sales 2024 * 1.55 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.49 x
P/E ratio 2024 *
177 x
P/E ratio 2025 *
145 x
Employees 725
Yield 2024 *
-
Yield 2025 *
-
Free-Float 53.55%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.57%
1 week+1.34%
Current month-2.57%
1 month-4.50%
3 months+1.15%
6 months+18.57%
Current year+2.12%
More quotes
1 week
5.23
Extreme 5.23
5.49
1 month
5.21
Extreme 5.21
5.58
Current year
5.13
Extreme 5.13
5.75
1 year
4.35
Extreme 4.35
5.75
3 years
4.28
Extreme 4.28
6.20
5 years
4.28
Extreme 4.28
8.88
10 years
4.28
Extreme 4.28
11.03
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 13-10-31
Founder 56 13-10-31
Director of Finance/CFO - 16-06-19
Members of the board TitleAgeSince
Director/Board Member 74 14-01-05
Founder 56 13-10-31
Director/Board Member 61 12-12-31
More insiders
Date Price Change Volume
24-03-28 5.3 -2.57% 35,930
24-03-27 5.44 +0.18% 28,577
24-03-26 5.43 +3.43% 127,669
24-03-25 5.25 -0.38% 478,154
24-03-22 5.27 +0.76% 78,147

Delayed Quote Toronto S.E., March 28, 2024 at 04:00 pm EDT

More quotes
Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
5.3 CAD
Average target price
6.642 CAD
Spread / Average Target
+25.31%
Consensus
  1. Stock
  2. Equities
  3. Stock Knight Therapeutics Inc. - Toronto S.E.